
|Videos|April 29, 2019
JAK Inhibition for the Management of Primary Myelofibrosis
JAK Inhibition for the Management of Primary Myelofibrosis
Advertisement
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019
- A 66-year old man presents to primary care physician with complaints of fatigue, headache, and abdominal discomfort when taking deep breaths
- PMH: depression
- PE: Splenomegaly ~7 cm below left costal margin
- Lab values:
- HGB: 9.2 g/dL
- Platelets: 242 x 109/L
- WBC: 26.2 x 109/L
- Serum LDH: 1400 U/L
- Serum EPO: 10.9 mU/mL
- Bone Marrow Biopsy:
- MF-3
- Circulating blasts, 1.1%
- JAK V617Fmutation; trisomy 8
- Peripheral Blood Smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































